TSE:RVX - Resverlogix Stock Price, Price Target & More

C$1.40 -0.07 (-4.76 %)
(As of 04/24/2018 03:04 AM ET)
Previous CloseC$1.40
Today's RangeC$1.40 - C$1.60
52-Week RangeC$1.23 - C$2.47
Volume27,600 shs
Average Volume41,170 shs
Market CapitalizationC$318.17 million
P/E RatioN/A
Dividend YieldN/A
Beta0.2

About Resverlogix (TSE:RVX)

Resverlogix Corp., an epigenetics company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibition in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.

Receive RVX News and Ratings via Email

Sign-up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolTSE:RVX
CUSIPN/A
Phone+1-403-2549252

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets-451.22%

Miscellaneous

EmployeesN/A
Outstanding Shares175,203,000

How to Become a New Pot Stock Millionaire

Resverlogix (TSE:RVX) Frequently Asked Questions

What is Resverlogix's stock symbol?

Resverlogix trades on the Toronto Stock Exchange (TSX) under the ticker symbol "RVX."

When is Resverlogix's next earnings date?

Resverlogix is scheduled to release their next quarterly earnings announcement on Friday, April, 27th 2018. View Earnings Estimates for Resverlogix.

Who are some of Resverlogix's key competitors?

Who are Resverlogix's key executives?

Resverlogix's management team includes the folowing people:
  • Mr. Donald J. McCaffrey, Co-Founder, Chairman Pres, CEO & Sec.
  • Mr. Aaron Bradley Cann CA, CPA, CBV, Chief Financial Officer
  • Mr. Kenneth Eugene Lebioda BA, Sr. VP of Bus. & Corp. Devel.
  • Dr. Jan O. Johansson M.D., Ph.D., Sr. VP of Medical Affairs
  • Dr. Michael Sweeney M.D., Sr. VP of Clinical Devel. (Age 57)

Has Resverlogix been receiving favorable news coverage?

News stories about RVX stock have trended somewhat positive on Tuesday, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Resverlogix earned a daily sentiment score of 0.11 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.96 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Resverlogix?

Shares of RVX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Resverlogix's stock price today?

One share of RVX stock can currently be purchased for approximately C$1.40.

How big of a company is Resverlogix?

Resverlogix has a market capitalization of C$318.17 million.

How can I contact Resverlogix?

Resverlogix's mailing address is 300-4820 Richard Rd SW, CALGARY, AB T3E 6L1, Canada. The biotechnology company can be reached via phone at +1-403-2549252.


MarketBeat Community Rating for Resverlogix (RVX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  82
MarketBeat's community ratings are surveys of what our community members think about Resverlogix and other stocks. Vote "Outperform" if you believe RVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Resverlogix (TSE:RVX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Resverlogix in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Resverlogix (TSE:RVX) Consensus Price Target History

Price Target History for Resverlogix (TSE:RVX)

Resverlogix (TSE:RVX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/15/2017Beacon SecuritiesReiterated RatingBuyView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Resverlogix (TSE:RVX) Earnings History and Estimates Chart

Earnings by Quarter for Resverlogix (TSE:RVX)

Resverlogix (TSE:RVX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.14)($0.14)($0.14)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.08)($0.08)($0.08)

Resverlogix (TSE RVX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2018        
12/14/2017Q2 2018C($0.13)ViewN/AView Earnings Details
9/13/2017Q1 2018C($0.14)C($0.19)ViewN/AView Earnings Details
7/25/2017Q4 2017C($0.06)C($0.15)ViewN/AView Earnings Details
3/17/2017Q3 2017C($0.16)ViewN/AView Earnings Details
12/13/2016Q2 2017C($0.06)C($0.10)ViewN/AView Earnings Details
9/14/2016Q1 2017C$0.08ViewN/AView Earnings Details
7/27/2016Q4 2016C($0.06)C($0.12)ViewN/AView Earnings Details
3/15/2016Q3 2016C($0.03)C($0.07)ViewN/AView Earnings Details
12/14/2015Q2 2016C($0.03)C($0.05)ViewN/AView Earnings Details
9/9/2015Q1 2016C($0.12)ViewN/AView Earnings Details
7/24/2015Q4 2015C($0.29)ViewN/AView Earnings Details
12/11/2014Q2 2015C$0.01ViewN/AView Earnings Details
9/12/2014Q1 2015C($0.22)ViewN/AView Earnings Details
7/29/2014Q4 2014C($0.03)C($0.05)ViewN/AView Earnings Details
3/17/2014Q3 2014C($0.03)ViewN/AView Earnings Details
12/13/2013Q2 2014C($0.03)ViewN/AView Earnings Details
9/13/2013Q1 2014C($1.02)ViewN/AView Earnings Details
7/26/2013Q4 2013C($0.16)ViewN/AView Earnings Details
3/13/2013Q3 2013C($0.18)ViewN/AView Earnings Details
12/10/2012Q2 2013C($0.14)ViewN/AView Earnings Details
9/14/2012Q1 2013C($0.10)ViewN/AView Earnings Details
7/30/2012Q4 2012C($0.10)ViewN/AView Earnings Details
3/15/2012Q3 2012C($0.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Resverlogix (TSE:RVX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Resverlogix (TSE RVX) Insider Trading and Institutional Ownership History

Insider Trading History for Resverlogix (TSE:RVX)

Resverlogix (TSE RVX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2016Michael SweeneyInsiderSell4,900C$0.96C$4,691.75
3/28/2016Michael SweeneyInsiderSell5,000C$0.98C$4,881.50
(Data available from 1/1/2013 forward)

Headlines

Resverlogix (TSE RVX) News Headlines

Source:
DateHeadline
Resverlogix Announces Proposed Offering of UnitsResverlogix Announces Proposed Offering of Units
finance.yahoo.com - April 17 at 10:34 AM
Resverlogix Corp. (RVX) to Post FY2019 Earnings of ($0.34) Per Share, Zacks Investment Research ForecastsResverlogix Corp. (RVX) to Post FY2019 Earnings of ($0.34) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - April 16 at 2:44 AM
Resverlogix Announces Two New Publications on Apabetalone in Kidney DiseaseResverlogix Announces Two New Publications on Apabetalone in Kidney Disease
finance.yahoo.com - March 28 at 10:28 AM
Stonegate Capital Partners Initiates Coverage on Resverlogix Corp. (TSX: RVX)Stonegate Capital Partners Initiates Coverage on Resverlogix Corp. (TSX: RVX)
finance.yahoo.com - March 20 at 10:22 AM
Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical TrialResverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial
finance.yahoo.com - March 19 at 10:27 AM
Toronto Exchanges Stock Review BELLUS Health Helius Medical Technologies Resverlogix and Crescita TherapeuticsToronto Exchanges Stock Review BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics
finance.yahoo.com - March 5 at 10:49 AM
Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of ApabetaloneResverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
finance.yahoo.com - February 26 at 10:15 AM
Who Are The Major Shareholders Of Resverlogix Corp (TSE:RVX)?Who Are The Major Shareholders Of Resverlogix Corp (TSE:RVX)?
finance.yahoo.com - February 15 at 9:17 AM
Resverlogix Highlights Key Accomplishments and 2018 TargetsResverlogix Highlights Key Accomplishments and 2018 Targets
finance.yahoo.com - February 8 at 9:26 AM
Today’s Research Reports on ESSA Pharma, Helius Medical Technologies, ProMetic Life Sciences and ResverlogixToday’s Research Reports on ESSA Pharma, Helius Medical Technologies, ProMetic Life Sciences and Resverlogix
finance.yahoo.com - February 6 at 8:36 AM
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial - GlobeNewswire (press release)Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial - GlobeNewswire (press release)
globenewswire.com - January 11 at 10:41 AM
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE TrialResverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
finance.yahoo.com - January 11 at 10:41 AM
Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing AgreementResverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement
finance.yahoo.com - January 8 at 10:50 AM
Resverlogix Corp. to Post Q3 2018 Earnings of ($0.09) Per Share, Zacks Investment Research Forecasts (RVX)Resverlogix Corp. to Post Q3 2018 Earnings of ($0.09) Per Share, Zacks Investment Research Forecasts (RVX)
www.americanbankingnews.com - December 22 at 2:26 PM
Resverlogix Announces Filing of Quarterly Financial Statements and Managements Discussion & Analysis - GlobeNewswire (press release)Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis - GlobeNewswire (press release)
globenewswire.com - December 15 at 10:24 AM
Resverlogix Announces Filing of Quarterly Financial Statements and Management’s Discussion & AnalysisResverlogix Announces Filing of Quarterly Financial Statements and Management’s Discussion & Analysis
finance.yahoo.com - December 15 at 10:24 AM
How Does Resverlogix Corp (TSE:RVX) Affect Your Portfolio Returns?How Does Resverlogix Corp (TSE:RVX) Affect Your Portfolio Returns?
finance.yahoo.com - December 12 at 3:31 PM
Natures Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1Nature's Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1
finance.yahoo.com - December 12 at 10:37 AM
Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen HepalinkResverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
finance.yahoo.com - December 4 at 10:07 AM
Resverlogix Corp. (RVX) Expected to Post FY2018 Earnings of ($0.20) Per ShareResverlogix Corp. (RVX) Expected to Post FY2018 Earnings of ($0.20) Per Share
www.americanbankingnews.com - November 20 at 7:18 AM
Resverlogix Corp. (RVX) Rating Reiterated by Beacon SecuritiesResverlogix Corp. (RVX) Rating Reiterated by Beacon Securities
www.americanbankingnews.com - November 18 at 6:04 AM
Resverlogix Announces Participation in Upcoming ConferencesResverlogix Announces Participation in Upcoming Conferences
finance.yahoo.com - November 4 at 12:52 PM
Resverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of ApabetaloneResverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
finance.yahoo.com - November 1 at 8:23 AM
BRIEF-Resverlogix Corp‍ entered into a Right of First Refusal Agreement with Hepalink USA IncBRIEF-Resverlogix Corp‍ entered into a Right of First Refusal Agreement with Hepalink USA Inc
www.businessinsider.com - October 27 at 3:43 PM
Canadian Healthcare Stocks under Review, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita TherapeuticsCanadian Healthcare Stocks under Review, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics
finance.yahoo.com - October 25 at 10:09 AM
Resverlogix Announces Right of First Refusal Agreement with Hepalink USA Inc. - GlobeNewswire (press release)Resverlogix Announces Right of First Refusal Agreement with Hepalink USA Inc. - GlobeNewswire (press release)
globenewswire.com - October 24 at 9:35 AM
Resverlogix Announces Right of First Refusal Agreement with Hepalink USA Inc.Resverlogix Announces Right of First Refusal Agreement with Hepalink USA Inc.
finance.yahoo.com - October 24 at 9:35 AM
Resverlogix Announces $87 Million Private Placement with Shenzhen HepalinkResverlogix Announces $87 Million Private Placement with Shenzhen Hepalink
globenewswire.com - October 14 at 7:32 AM
Resverlogix Announces $87 Million Private Placement with Shenzhen HepalinkResverlogix Announces $87 Million Private Placement with Shenzhen Hepalink
globenewswire.com - October 14 at 7:32 AM
Healthcare Stocks: Is Now The Time To Buy Resverlogix Corp (TSX:RVX)?Healthcare Stocks: Is Now The Time To Buy Resverlogix Corp (TSX:RVX)?
finance.yahoo.com - October 12 at 3:21 PM
Resverlogix Announces Annual and Special Meeting of ShareholdersResverlogix Announces Annual and Special Meeting of Shareholders
finance.yahoo.com - October 3 at 11:55 AM
Resverlogix Announces Filing of Quarterly Financial Statements and Managements Discussion & AnalysisResverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
finance.yahoo.com - September 13 at 9:45 PM
Resverlogix Closes Extension of Maturity Date of Loan and Announces Private PlacementResverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
finance.yahoo.com - September 5 at 7:41 AM
Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix Ongoing BETonMACE TrialSuccessful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
finance.yahoo.com - August 30 at 8:46 AM
BRIEF-Resverlogix announces extension of maturity date of loan and expression of interest on strategic transactionBRIEF-Resverlogix announces extension of maturity date of loan and expression of interest on strategic transaction
www.reuters.com - August 29 at 7:29 AM
Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic TransactionResverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
finance.yahoo.com - August 29 at 7:29 AM
Resverlogix (RVX) Reports Fiscal Year 2017 ResultsResverlogix (RVX) Reports Fiscal Year 2017 Results
finance.yahoo.com - August 14 at 3:36 PM
Brokers Issue Forecasts for Resverlogix Corp.s Q1 2018 Earnings (TSE:RVX)Brokers Issue Forecasts for Resverlogix Corp.'s Q1 2018 Earnings (TSE:RVX)
www.americanbankingnews.com - August 3 at 1:58 PM
CORRECTION FROM SOURCE: IIROC Trade Halt - Resverlogix Corp.CORRECTION FROM SOURCE: IIROC Trade Halt - Resverlogix Corp.
finance.yahoo.com - July 26 at 7:01 AM
IIROC Trading Halt - RVXIIROC Trading Halt - RVX
finance.yahoo.com - July 26 at 7:01 AM
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE TrialResverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
finance.yahoo.com - July 26 at 7:01 AM
IIROC Trade Resumption - Resverlogix Corp.IIROC Trade Resumption - Resverlogix Corp.
finance.yahoo.com - July 26 at 7:01 AM
IIROC Trade Resumption - RVXIIROC Trade Resumption - RVX
finance.yahoo.com - July 26 at 7:01 AM
Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
finance.yahoo.com - July 26 at 7:01 AM
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical TrialResverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
finance.yahoo.com - July 11 at 7:21 AM
Resverlogix Randomizes First Patient in Taiwan/mainland China Portion of the Phase 3 BETonMACE Clinical TrialResverlogix Randomizes First Patient in Taiwan/mainland China Portion of the Phase 3 BETonMACE Clinical Trial
finance.yahoo.com - July 11 at 7:21 AM
Daily Coverage on Healthcare Stocks: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita TherapeuticsDaily Coverage on Healthcare Stocks: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics
finance.yahoo.com - July 5 at 10:19 AM
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017 - PR Newswire (press release)Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017 - PR Newswire (press release)
www.prnewswire.com - June 5 at 7:09 AM
Resverlogix celebra un simposio centrado en epigenética en el ERA-EDTA Congress de Madrid, España - PR Newswire (Comunicado de prensa)Resverlogix celebra un simposio centrado en epigenética en el ERA-EDTA Congress de Madrid, España - PR Newswire (Comunicado de prensa)
www.prnewswire.com - June 1 at 10:18 PM
Resverlogix recibe la aprobación de Health Canada para proceder con el ensayo clínico en enfermedad de Fabry - PR Newswire (Comunicado de prensa)Resverlogix recibe la aprobación de Health Canada para proceder con el ensayo clínico en enfermedad de Fabry - PR Newswire (Comunicado de prensa)
www.prnewswire.com - June 1 at 10:18 PM

SEC Filings

Resverlogix (TSE:RVX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Resverlogix (TSE RVX) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.